Get the Stockscreener App
5.67
1.98%
0.11
After Hours:
5.70
0.03
+0.53%
Ardelyx Inc stock is traded at $5.67, with a volume of 3.29M.
It is up +1.98% in the last 24 hours and up +13.40% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.56
Open:
$5.54
24h Volume:
3.29M
Relative Volume:
0.68
Market Cap:
$1.34B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-18.09
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
+5.78%
1M Performance:
+13.40%
6M Performance:
-6.74%
1Y Performance:
-37.83%
1-Day Range:
$5.45
$5.76
1-Week Range:
$5.15
$5.76
52-Week Range:
$4.32
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.67 | 1.34B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
State Street Corp Reduces Stake in Ardelyx Inc: Analyzing the Im - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Upgraded to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 Shares - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) PT at $9.42 - MarketBeat
Ardelyx (NASDAQ:ARDX) Given New $8.00 Price Target at Piper Sandler - MarketBeat
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - The Manila Times
Ardelyx, Inc. to Host Conference Call on February 20, 2025, for Financial Results and Business Update - Nasdaq
Ardelyx Q4 Earnings Call: Key Financial Metrics and Strategic Updates Coming February 20 - StockTitan
High Growth Tech Stocks To Watch In January 2025 - Simply Wall St
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? - MSN
What Analysts Are Saying About Ardelyx Stock - Benzinga
Ardelyx (NASDAQ:ARDX) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Wedbush Weighs in on Ardelyx's FY2024 Earnings (NASDAQ:ARDX) - MarketBeat
Biotech Déjà vu – Insider Weekends - substack.com
Ardelyx (NASDAQ:ARDX) Shares Gap Up on Insider Buying Activity - MarketBeat
Ardelyx spikes as chairman buys nearly $1M worth of stock - MSN
Chairman David Mott Bets $1M on Ardelyx--Is This Biotech Stock Set to Skyrocket? - Yahoo Finance
Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, Josh Resnick, Bill Ackman, Warren Buffett, George Soros, Saba Capital, Ardelyx Inc (ARDX), RH (RH), and More - Insider Monkey
Ardelyx stock spikes after insider purchase (ARDX:NASDAQ) - Seeking Alpha
Ardelyx, Inc. (NASDAQ:ARDX) Director Buys $993,010.00 in Stock - MarketBeat
Ardelyx director David Mott buys $992,671 in company stock - MSN
Director David Mott Acquires 199,000 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx Shares Rise as Chairman Mott Increases Stake in Company -January 22, 2025 at 06:41 pm EST - Marketscreener.com
Ardelyx Shares Rise as Chairman Mott Increases Stake in Company - MarketWatch
Ardelyx director David Mott buys $992,671 in company stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Forecasts Ardelyx FY2025 Earnings - MarketBeat
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Recent 15% pullback isn't enough to hurt long-term Ardelyx (NASDAQ:ARDX) shareholders, they're still up 504% over 3 years - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns Neutral Rating from HC Wainwright - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Shares Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Up 8.3%Still a Buy? - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.7%Time to Sell? - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Up 8.3%What's Next? - MarketBeat
Ardelyx's Ibsrela sales beat expectations, shares surge By Investing.com - Investing.com Canada
Ardelyx reports strong 2024 sales, eyes growth in 2025 By Investing.com - Investing.com Canada
Ardelyx provides update on commercial progress; shares up 8% - MSN
Ardelyx reports strong 2024 sales, eyes growth in 2025 - Investing.com
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities - The Manila Times
Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates - StockTitan
Ardelyx CEO Michael Raab sells $221k in stock - Investing.com India
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):